![]() Patients know the physical and emotional weight of their illnesses, for this reason, they are the most suitable for proposing and evaluating the situations they face every day, inside and outside the hospital, and we are integrating their voices to continuously improve and evolve the treatments that should serve them to live active and fulfilling lives.”Įxperts discuss how to better care for respiratory patientsĪs a Congress sponsor, Chiesi brings together international expertise regarding the management of chronic respiratory diseases that will be addressed at the three company-sponsored symposia: People with chronic respiratory diseases deserve to lead a life that is not fully affected by their disease. The innovation aims to relieve the burden of disease in the day-to-day life of patients.Īlessandro Chiesi, Chief Commercial Officer at Chiesi Group said, “ Our research is not driven by short-term profitability goals, but by patient s ’ long-term needs. Chiesi strengthens its commitment to the care of COPD patients by making the therapy available in DPI as well as in pressurised Metered-Dose Inhaler (pMDI) devices to best meet individual patients’ needs. They can now benefit from the availability of Chiesi’s extrafine triple combination therapy delivered through a Dry Powder Inhaler (DPI) device. ![]() Chiesi Group has organised three symposia at the Congress, focusing on improving care for people living with COPD and asthmaīarcelona, Spain, Septem– At the 2022 European Respiratory Society (ERS) International Congress in Barcelona, Chiesi Group, the international research-focused biopharmaceutical, and healthcare group, is focusing on ways in which we can improve the care for people living with chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).Īt the congress, Chiesi is presenting a new treatment option for adult patients with moderate to severe COPD who are not adequately treated with existing alternatives.At the European Respiratory Society Congress, Chiesi Group presents an additional option to address the needs of COPD patients: Chiesi’s extrafine triple combination therapy delivered through a Dry Powder Inhaler device.Chronic obstructive pulmonary disease, or COPD, is the third leading cause of death in the world, causing 300,000 annual deaths in Europe 1. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |